menu
    • menu

    Company profile for Aditxt

    NEW Drugs in Dev: 2
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. Our immune reprogramming technology called Apoptotic DNA Immunotherapy™ (ADi™) is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. Our immune monitor...
    We are a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. Our immune reprogramming technology called Apoptotic DNA Immunotherapy™ (ADi™) is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. Our immune monitoring technology called Aditxtscore™ is designed to provide a personalized comprehensive profile of the immune system

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AditxtUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Richmond, VA 23219
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aditxt.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aditxt/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aditxt's Ignite Proteomics Names Jeff Busch as CEO
    Aditxt's Ignite Proteomics Names Jeff Busch as CEO

    19 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260319940379/en/Aditxt-Subsidiary-Ignite-Proteomics-Appoints-Public-Company-Veteran-Jeff-Busch-as-Chief-Executive-Officer

    BUSSINESSWIRE
    19 Mar 2026
    Share Share
    Aditxt Acquires Ignite Proteomics To Address A Critical
    Aditxt Acquires Ignite Proteomics To Address A Critical

    13 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260313909767/en/Aditxt-Acquires-Ignite-Proteomics-to-Address-a-Critical-Challenge-in-Cancer-Care-Optimizing-Therapy-Selection

    BUSSINESSWIRE
    13 Mar 2026
    Share Share
    Aditxt Announces 1-For-8 Reverse Stock
    Aditxt Announces 1-For-8 Reverse Stock

    05 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260305834344/en/Aditxt-Inc.-NASDAQ-ADTX-Announces-1-for-8-Reverse-Stock-Split-Effective-at-the-Open-of-Trading-on-March-9-2026

    BUSSINESSWIRE
    05 Mar 2026
    Share Share
    Aditxt Reveals Growth Plans for Bitxbio and Pearsanta IPO
    Aditxt Reveals Growth Plans for Bitxbio and Pearsanta IPO

    18 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251118746973/en/Aditxt-Provides-Updates-on-its-Growth-Vision-for-bitXbio-Planned-Digital-Asset-Treasury-Pearsantas-Planned-IPO-And-Evofems-Plan-to-Regain-a-National-Listing

    BUSINESSWIRE
    18 Nov 2025
    Share Share
    Aditxt To Implement 1-For-113 Reverse Stock Split On November 3
    Aditxt To Implement 1-For-113 Reverse Stock Split On November 3

    29 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251029193797/en/Aditxt-Inc.-NASDAQ-ADTX-Announces-1-for-113-Reverse-Stock-Split-Effective-at-the-Open-of-Trading-on-November-3-2025

    BUSINESSWIRE
    29 Oct 2025
    Share Share
    Pearsanta Begins First Human Trial for Endometriosis Diagnostic
    Pearsanta Begins First Human Trial for Endometriosis Diagnostic

    27 Oct 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251027553743/en/Aditxt-Subsidiary-Pearsanta-Begins-Enrollment-in-First-Human-Study-of-Blood-Based-Diagnostic-for-Endometriosis-a-Condition-Affecting-190-Million-Women-Worldwide-and-Representing-a-%241.45-Billion-Global-Market

    BUSINESS WIRE
    27 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search